GlassScriptPhysician profile
Jennifer Melcher
NPI 1437692597
$8,483.83
in general payments reported to CMS, 2019-2025
33 companies · $2,651 in 2025
The $2,651 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,553 · 2022: $1,824 · 2023: $1,078 · 2024: $1,378 · 2025: $2,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,086 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,086.17 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $1,063.44 | 2025 | Rapiblyk |
| Novartis Pharmaceuticals Corporation | $784.35 | 2021-2025 | |
| Amgen INC. | $651.90 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $594.12 | 2021-2025 | Farxiga, Andexxa, Wainua |
| Pfizer INC. | $587.08 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $560.98 | 2021-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $496.93 | 2022-2025 | Assure Wcd |
| Abbott Laboratories | $432.80 | 2022-2025 | Eterna, Cardiomems, Proclaim |
| Janssen Pharmaceuticals, INC | $371.21 | 2021-2024 | Xarelto |
| Esperion Therapeutics, INC. | $366.32 | 2021-2025 | Nexletol |
| Chiesi USA, INC. | $318.17 | 2021-2023 | Kengreal, Cleviprex |
| E.R. Squibb & Sons, L.L.C. | $313.18 | 2021-2025 | Eliquis, Camzyos |
| Scpharmaceuticals INC. | $307.48 | 2023-2025 | |
| Medtronic, INC. | $304.00 | 2021-2023 | Corevalve Evolut R |
| Novo Nordisk INC | $183.34 | 2024-2025 | Wegovy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $176.11 | 2022 | |
| Jenavalve Technology, INC. | $162.44 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $106.86 | 2022-2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $104.20 | 2021-2023 | Evkeeza, Praluent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.73 | 2024-2025 | Jardiance |
| Boston Scientific Corporation | $80.73 | 2022-2025 | Watchman Flx |
| Lexicon Pharmaceuticals, INC. | $79.31 | 2023-2024 | Inpefa |
| Amarin Pharma, INC. | $74.71 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $49.86 | 2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $35.76 | 2021-2025 | |
| W. L. Gore & Associates, INC. | $27.95 | 2022 | |
| Merck Sharp & Dohme LLC | $27.77 | 2021-2023 | Verquvo |
| Cvrx, INC. | $27.45 | 2024 | Barostim Neo System |
| Daiichi Sankyo INC. | $26.95 | 2023 | Injectafer |
| Corcept Therapeutics | $26.94 | 2025 | Korlym |
| Alnylam Pharmaceuticals INC. | $24.88 | 2025 | Onpattro |
| Endotronix, INC. | $20.85 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Akcea Therapeutics, INC. | $14.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Melcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.